SILO Point Capital Inc

Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics

Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics

NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, today announced that Founder and CEO Eric Weisblum will participate in the “Investing in Psychedelics Series: Building Value Through IP” virtual conference hosted by The Canadian Securities Exchange (CSE), CFN Media Group (OTCQB: CNFN) and Zuber Lawler on Wednesday, January 20, 2021. The live panel discussion is scheduled to begin at 1 PM EST. and will be followed by a Q&A session.

For more information and to register for this free conference, please visit the conference website at   or contact

About ‘Investing in Psychedelics’ Conference

The virtual conference will feature live panels with moderators. Panel participants will consist of company executives, IP specialists, and bankers across three sessions. Attendees will be able to submit questions to the panelists via the moderators. Company executives will be interviewed ahead of the live event and the recorded videos will be shared with conference registrants.

About Silo Pharma

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.  For more information, visit .

Investor Relations Contact:                                     

Hayden IR

Brett Maas

646-536-7331

Email:   













EN
19/01/2021

Underlying

SILOPoint Capital Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Point Capital Inc

 PRESS RELEASE
Free
SILO Point Capital I...

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on...

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS, NJ, Jan. 10, 2023 (GLOBE NEWSWIRE) --   (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a progress update on its sponsored research study with the University of California, San Francisco (UCSF)...

January 10, 2023 1 EN
 PRESS RELEASE
Free
SILO Point Capital I...

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis SPU-21 effective in controlling arthritis progression.  SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide  ENGLEWOOD CLIFFS, NJ, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of...

December 30, 2022 1 EN
 PRESS RELEASE
Free
SILO Point Capital I...

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeli...

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) --  Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today issued a letter to shareholders highlighting the Company’s progress and potential for its portfolio of novel, IP-protected technologies and assets developed in collaboration with world-class medical research partners. The ...

December 1, 2022 1 EN
 PRESS RELEASE
Free
SILO Point Capital I...

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tis...

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue Initial data from study expected in first quarter 2023 ENGLEWOOD CLIFFS, NJ, Nov. 21, 2022 (GLOBE NEWSWIRE) --   (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinit...

November 21, 2022 1 EN
 PRESS RELEASE
Free
SILO Point Capital I...

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IN...

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. The objective of this safety evaluation study, conducted by Experimur, a Frontage Company, is to evaluate the tolerabilit...

November 11, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch